Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
PEG-modified recombinant mammalian urate oxidase (PEG-uricase) is being developed as a treatment for patients with chronic gout who are intolerant of, or refractory to, available therapy for controlling hyperuricemia. In an open-label phase I trial, single subcutaneous injections of PEG-uricase (4 to 24 mg) were administered to 13 such subjects (11 had tophaceous gout), whose plasma uric acid concentration (pUAc) was 11.3 ± 2.1 mg/dl (mean ± SD). By day seven after injection of PEG-uricase, pUAc had declined by an average of 7.9 mg/dl and had normalized in 11 subjects, whose mean pUAc decreased to 2.8 ± 2.2 mg/dl. At doses of 8, 12, and 24 mg, the mean pUAc at 21 days after injection remained no more than 6 mg/dl. In eight subjects, plasma uricase activity was still measurable at 21 days after injection (half-life 10.5 to 19.9 days). In the other five subjects, plasma uricase activity could not be detected beyond ten days after injection; this was associated with the appearance of relatively low-titer IgM and IgG antibodies against PEG-uricase. Unexpectedly, these antibodies were directed against PEG itself rather than the uricase protein. Three PEG antibody-positive subjects had injection-site reactions at 8 to 9 days after injection. Gout flares in six subjects were the only other significant adverse reactions, and PEG-uricase was otherwise well tolerated. A prolonged circulating life and the ability to normalize plasma uric acid in markedly hyperuricemic subjects suggest that PEG-uricase could be effective in depleting expanded tissue stores of uric acid in subjects with chronic or tophaceous gout. The development of anti-PEG antibodies, which may limit efficacy in some patients, is contrary to the general assumption that PEG is non-immunogenic. PEG immunogenicity deserves further investigation, because it has potential implications for other PEGylated therapeutic agents in clinical use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





![Figure 6 Competition ELISA to determine the specificity of IgG antibody against PEG-uricase. Increasing amounts of the indicated materials were added to aliquots of plasma obtained from subject 013 on day 14 after subcutaneous injection of 12 mg of PEG-modified recombinant mammalian urate oxidase (PEG-uricase). After incubation overnight, these mixtures were tested at a 1:60 dilution in the ELISA for IgG antibody against PEG-uricase. (a) 'Uricase' is the unmodified recombinant protein used in PEG-uricase, and 'PEG 10000' is 10 K monomethoxyPEG (mPEG) conjugated with glycine instead of uricase protein. 'PEG-PNP' is bacterial purine nucleoside phosphorylase conjugated with mPEG of molecular mass 5 kDa, prepared as described [18]. (b) 'PEG 350' and 'PEG 2000' are unconjugated, nonactivated mPEGs of molecular masses 350 and 2,000 Da. 'PEG 5000' and 'PEG 10000' are p-nitrophenyl carbonate-activated mPEGs of the indicated molecular masses conjugated with glycine.](https://figures.cochat.ai/paper-figures/f8a8191cc8f9401e9fb6bf56f5998352/control-of-hyperuricemia-in-subjects-with-refractory-gout-and-induction-of-figure-6.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a Phase I study of refractory gout, patients were treated with a PEG-uricase therapy. About one third of the treatment group, who had previously been treated with pegylated therapies at some point, had previously developed anti-PEG antibodies in the body. This resulted in lower AUC’s and poor efficacy of the PEG-uricase treatment [80].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [80]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
The metabolic and molecular bases of inherited disease
Chen, Y.-T. (2001) · Medical Entomology and Zoology · Cited by 6,928
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431
Molecular identification of a danger signal that alerts the immune system to dying cells
Shi, Y., Evans, J. E., & Rock, K. L. (2003) · Nature · doi:10.1038/nature01991 · Cited by 1,684
Abuchowski, A., McCoy, J. R., Palczuk, N. C., van Es, T., & Davis, F. F. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40292-4 · Cited by 1,274
Kelley's Textbook of Rheumatology
(2013) · Elsevier eBooks · doi:10.1016/c2009-1-62542-9 · Cited by 1,101
Poly(ethylene glycol): Chemistry and Biological Applications
(1997) · ACS Symposium Series · doi:10.1021/bk-1997-0680 · Cited by 646
Avramis, V. I., Sencer, S., Periclou, A. P., Sather, H., Bostrom, B. C., Cohen, L. J., Ettinger, A. G., Ettinger, L. J., Franklin, J., Gaynon, P. S., et al. (2002) · Blood · doi:10.1182/blood.v99.6.1986 · Cited by 492
Goldman, S. C., Holcenberg, J. S., Finklestein, J. Z., Hutchinson, R., Kreissman, S., Johnson, F. L., Tou, C., Harvey, E., Morris, E., & Cairo, M. S. (2001) · Blood · doi:10.1182/blood.v97.10.2998 · Cited by 477
A specific enzyme defect in gout associated with overproduction of uric acid.
Kelley, W. N., Rosenbloom, F. M., Henderson, J. F., & Seegmiller, J. E. (1967) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.57.6.1735 · Cited by 475
Research works printed but not linked: 1
- Ganson N, Kelly SJ, Scarlett E, Sundy JS, Hershfield MS: Antibodies to polyethylene glycol (PEG) during phase I investigation of PEG-urate oxidase (PEG-uricase; Puricase®) for refractory gout [abstract]. Arthritis Rheum. 2004, 50: s338-
Cited by
Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
Knop, K., Hoogenboom, R., Fischer, D., & Schubert, U. S. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.200902672 · Cited by 3,533
The Impact of PEGylation on Biological Therapies
Veronese, F. M., & Mero, A. (2008) · BioDrugs · doi:10.2165/00063030-200822050-00004 · Cited by 1,034
The accelerated blood clearance (ABC) phenomenon: Clinical challenge and approaches to manage
Abu Lila, A. S., Kiwada, H., & Ishida, T. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.07.026 · Cited by 721
Armstrong, J. K., Hempel, G., Koling, S., Chan, L. S., Fisher, T., Meiselman, H. J., & Garratty, G. (2007) · Cancer · doi:10.1002/cncr.22739 · Cited by 699
Hwang, D., Ramsey, J. D., & Kabanov, A. V. (2020) · Advanced drug delivery reviews · doi:10.1016/j.addr.2020.09.009 · Cited by 699
Anti-PEG antibodies in the clinic: Current issues and beyond PEGylation
Zhang, P., Sun, F., Liu, S., & Jiang, S. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.06.040 · Cited by 688
PEGylation of therapeutic proteins
Jevševar, S., Kunstelj, M., & Porekar, V. G. (2010) · Biotechnology Journal · doi:10.1002/biot.200900218 · Cited by 681
Effects of glycosylation on the stability of protein pharmaceuticals
Solá, R. J., & Griebenow, K. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21504 · Cited by 646
Polymer–drug conjugation, recent achievements and general strategies
Pasut, G., & Veronese, F. M. (2007) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2007.05.008 · Cited by 616
Anti‐ PEG immunity: emergence, characteristics, and unaddressed questions
Yang, Q., & Lai, S. K. (2015) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1339 · Cited by 593
Chen, B.-M., Cheng, T.-L., & Roffler, S. R. (2021) · ACS Nano · doi:10.1021/acsnano.1c05922 · Cited by 563
Shi, D., Beasock, D., Fessler, A., Szebeni, J., Ljubimova, J. Y., Afonin, K. A., & Dobrovolskaia, M. A. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114079 · Cited by 535
Delivery of Therapeutic Proteins
Pisal, D. S., Kosloski, M. P., & Balu-Iyer, S. V. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22054 · Cited by 532
Polymeric nanomedicine for cancer therapy
Park, J. H., Lee, S., Kim, J.-H., Park, K., Kim, K., & Kwon, I. C. (2008) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2007.09.003 · Cited by 506
Ibrahim, M., Ramadan, E., Elsadek, N. E., Emam, S. E., Shimizu, T., Ando, H., Ishima, Y., Elgarhy, O. H., Sarhan, H. A., Hussein, A. K., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.09.031 · Cited by 465
PEG conjugates in clinical development or use as anticancer agents: An overview
Pasut, G., & Veronese, F. M. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.02.010 · Cited by 457
Evolutionary history and metabolic insights of ancient mammalian uricases
Kratzer, J. T., Lanaspa, M. A., Murphy, M. N., Cicerchi, C., Graves, C. L., Tipton, P. A., Ortlund, E. A., Johnson, R. J., & Gaucher, E. A. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320393111 · Cited by 361
Rai, R., Alwani, S., & Badea, I. (2019) · Polymers · doi:10.3390/polym11040745 · Cited by 350
Impact of Product-Related Factors on Immunogenicity of Biotherapeutics
Singh, S. K. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22276 · Cited by 350
The Immunogenicity of Polyethylene Glycol: Facts and Fiction
Schellekens, H., Hennink, W. E., & Brinks, V. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1067-7 · Cited by 340
Administration, distribution, metabolism and elimination of polymer therapeutics
Markovsky, E., Baabur-Cohen, H., Eldar-Boock, A., Omer, L., Tiram, G., Ferber, S., Ofek, P., Polyak, D., Scomparin, A., & Satchi-Fainaro, R. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.12.021 · Cited by 313
PEG-uricase in the management of treatment-resistant gout and hyperuricemia
Sherman, M. R., Saifer, M. G. P., & Perez-Ruiz, F. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.06.011 · Cited by 291
Poly(ethylene glycol)-Prodrug Conjugates: Concept, Design, and Applications
Banerjee, S. S., Aher, N., Patil, R., & Khandare, J. (2012) · Journal of Drug Delivery · doi:10.1155/2012/103973 · Cited by 282
Ponce, R., Abad, L., Amaravadi, L., Gelzleichter, T., Gore, E., Green, J., Gupta, S., Herzyk, D., Hurst, C., Ivens, I. A., et al. (2009) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2009.03.012 · Cited by 270
Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics
Verhoef, J. J. F., Carpenter, J. F., Anchordoquy, T. J., & Schellekens, H. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.08.015 · Cited by 267
Lipsky, P. E., Calabrese, L. H., Kavanaugh, A., Sundy, J. S., Wright, D., Wolfson, M., & Becker, M. A. (2014) · Arthritis Research & Therapy · doi:10.1186/ar4497 · Cited by 266
Self-citationHershfield, M. S., Ganson, N. J., Kelly, S. J., Scarlett, E. L., Jaggers, D. A., & Sundy, J. S. (2014) · Arthritis Research & Therapy · doi:10.1186/ar4500 · Cited by 266
Self-citationKang, J. S., DeLuca, P. P., & Lee, K. C. (2009) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210902907847 · Cited by 252
PEGylated therapeutics in the clinic
Gao, Y., Joshi, M., Zhao, Z., & Mitragotri, S. (2024) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10600 · Cited by 233
Chen, B.-M., Su, Y.-C., Chang, C.-J., Burnouf, P.-A., Chuang, K.-H., Chen, C.-H., Cheng, T.-L., Chen, Y.-T., Wu, J.-Y., & Roffler, S. R. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.6b03109 · Cited by 239
Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology
Broen, J. C. A., & van Laar, J. M. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0374-8 · Cited by 235
Gout therapeutics: new drugs for an old disease
Burns, C. M., & Wortmann, R. L. (2011) · The Lancet · doi:10.1016/s0140-6736(10)60665-4 · Cited by 237
High-resolution ultrasonography of the first metatarsal phalangeal joint in gout: a controlled study
Wright, S. A., Filippucci, E., McVeigh, C., Grey, A., McCarron, M., Grassi, W., Wright, G. D., & Taggart, A. J. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.062802 · Cited by 228
Sundy, J. S., Ganson, N. J., Kelly, S. J., Scarlett, E. L., Rehrig, C. D., Huang, W., & Hershfield, M. S. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22403 · Cited by 221
Self-citationMima, Y., Hashimoto, Y., Shimizu, T., Kiwada, H., & Ishida, T. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00144 · Cited by 209
Toxicity and immunogenicity concerns related to PEGylated-micelle carrier systems: a review
Shiraishi, K., & Yokoyama, M. (2019) · Science and Technology of Advanced Materials · doi:10.1080/14686996.2019.1590126 · Cited by 208
Optimizing current treatment of gout
Rees, F., Hui, M., & Doherty, M. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.32 · Cited by 199
Challenges and approaches for the development of safer immunomodulatory biologics
Sathish, J. G., Sethu, S., Bielsky, M.-C., de Haan, L., French, N. S., Govindappa, K., Green, J., Griffiths, C. E. M., Holgate, S., Jones, D., et al. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3974 · Cited by 185
Half‐Life Extension of Biopharmaceuticals using Chemical Methods: Alternatives to PEGylation
van Witteloostuijn, S. B., Pedersen, S. L., & Jensen, K. J. (2016) · ChemMedChem · doi:10.1002/cmdc.201600374 · Cited by 183
Role of the methoxy group in immune responses to mPEG-protein conjugates
Sherman, M. R., Williams, L. D., Sobczyk, M. A., Michaels, S. J., & Saifer, M. G. P. (2012) · Bioconjugate Chemistry · doi:10.1021/bc200551b · Cited by 185
Sundy, J. S., Becker, M. A., Baraf, H. S. B., Barkhuizen, A., Moreland, L. W., Huang, W., Waltrip, R. W., Maroli, A. N., Horowitz, Z., & Pegloticase Phase 2 Study Investigators (2008) · Arthritis & Rheumatism · doi:10.1002/art.23810 · Cited by 181
Self-citationLiu, M., Wang, Y., Zhang, Y.-B., Hu, D., Tang, L., Zhou, B., & Yang, L. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02112-8 · Cited by 208
The Mystery of Antibodies Against Polyethylene Glycol (PEG) - What do we Know?
Lubich, C., Allacher, P., de la Rosa, M., Bauer, A., Prenninger, T., Horling, F. M., Siekmann, J., Oldenburg, J., Scheiflinger, F., & Reipert, B. M. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1961-x · Cited by 164
Reinders, M. K., van Roon, E. N., Jansen, T. L. T. A., Delsing, J., Griep, E. N., Hoekstra, M., van de Laar, M. A. F. J., & Brouwers, J. R. B. J. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.083071 · Cited by 162
PEGylated Biopharmaceuticals: Current Experience and Considerations for Nonclinical Development
Ivens, I. A., Achanzar, W., Baumann, A., Brändli-Baiocco, A., Cavagnaro, J., Dempster, M., Depelchin, B. O., Irizarry Rovira, A. R., Dill-Morton, L., Lane, J. H., et al. (2015) · Toxicologic Pathology · doi:10.1177/0192623315591171 · Cited by 158
Lincoff, A. M., Mehran, R., Povsic, T. J., Zelenkofske, S. L., Huang, Z., Armstrong, P. W., Steg, P. G., Bode, C., Cohen, M. G., Buller, C. E. H., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00515-2 · Cited by 167
Luo, D., Li, N., Carter, K. A., Lin, C., Geng, J., Shao, S., Huang, W., Qin, Y., Atilla‐Gokcumen, G. E., & Lovell, J. F. (2016) · Small · doi:10.1002/smll.201503966 · Cited by 162
Discussion about Several Potential Drawbacks of PEGylated Therapeutic Proteins
Zhang, F., Liu, M.-R., & Wan, H. (2013) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b13-00661 · Cited by 157
Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines
Risma, K., Edwards, K. M., Hummell, D. S., Little, F. F., Norton, A. E., Stallings, A. P., Wood, R. A., & Milner, J. D. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.04.002 · Cited by 162
Immunogenicity to Biologics: Mechanisms, Prediction and Reduction
Sethu, S., Govindappa, K., Alhaidari, M., Pirmohamed, M., Park, K., & Sathish, J. G. (2012) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-012-0189-7 · Cited by 168
Hershfield, M. S., Roberts, L. J., Ganson, N. J., Kelly, S. J., Santisteban, I., Scarlett, E., Jaggers, D., & Sundy, J. S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001072107 · Cited by 144
Self-citationQi, Y., Simakova, A., Ganson, N. J., Li, X., Luginbuhl, K. M., Özer, İ., Liu, W., Hershfield, M. S., Matyjaszewski, K. A., & Chilkoti, A. (2016) · Nature Biomedical Engineering · doi:10.1038/s41551-016-0002 · Cited by 142
Self-citationRasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout
Cammalleri, L., & Malaguarnera, M. (2007) · International Journal of Medical Sciences · doi:10.7150/ijms.4.83 · Cited by 131
Grenier, P., Viana, I. M. D. O., Lima, E. M., & Bertrand, N. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.08.022 · Cited by 127
Moreno, A. M., Palmer, N. D., Alemán, F., Chen, G., Pla, A., Jiang, N. J., Chew, W. L., Law, M., & Mali, P. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0431-2 · Cited by 134
Chen, E., Chen, B., Su, Y.-C., Chang, Y., Cheng, T., Barenholz, Y., & Roffler, S. R. (2020) · ACS Nano · doi:10.1021/acsnano.9b07218 · Cited by 137
Analytical Measurement of PEGylated Molecules
Cheng, T., Chuang, K.-H., Chen, B., & Roffler, S. R. (2012) · Bioconjugate Chemistry · doi:10.1021/bc200478w · Cited by 145
The management of tumor lysis syndrome
Rampello, E., Fricia, T., & Malaguarnera, M. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0581 · Cited by 125
Advanced Strategies for Modulation of the Material–Macrophage Interface
Huyer, L. D., Pascual‐Gil, S., Wang, Y., Mandla, S., Yee, B., & Radisic, M. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201909331 · Cited by 127
Eggebeen, A. T. (2007) · PubMed · Cited by 123
Anwendung von Poly(ethylenglycol) beim Wirkstoff‐Transport: Vorteile, Nachteile und Alternativen
Knop, K., Hoogenboom, R., Fischer, D., & Schubert, U. S. (2010) · Angewandte Chemie · doi:10.1002/ange.200902672 · Cited by 132
Bioinspired Shielding Strategies for Nanoparticle Drug Delivery Applications
Gulati, N. M., Stewart, P. L., & Steinmetz, N. F. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00292 · Cited by 126
Effects of pharmaceutical PEGylation on drug metabolism and its clinical concerns
Zhang, X., Wang, H., Ma, Z., & Wu, B. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.967679 · Cited by 121
Anti-PEG antibodies: Current situation and countermeasures
Fu, J., Wu, E., Li, G., Wang, B., & Zhan, C. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102163 · Cited by 122
Selection of Nucleic Acid Aptamers Targeting Tumor Cell-Surface Protein Biomarkers
Mercier, M.-C., Dontenwill, M., & Choulier, L. (2017) · Cancers · doi:10.3390/cancers9060069 · Cited by 113
Saifer, M. G. P., Williams, L. D., Sobczyk, M. A., Michaels, S. J., & Sherman, M. R. (2013) · Molecular Immunology · doi:10.1016/j.molimm.2013.07.014 · Cited by 112
Hsieh, Y.-C., Wang, H.-E., Lin, W.-W., Roffler, S. R., Cheng, T.-C., Su, Y.-C., Li, J.-J., Chen, C., Huang, C.-H., Chen, B., et al. (2018) · Theranostics · doi:10.7150/thno.22164 · Cited by 116
Povsic, T. J., Vavalle, J. P., Aberle, L. H., Kasprzak, J. D., Cohen, M. G., Mehran, R., Bode, C., Buller, C. E. H., Montalescot, G., Cornel, J. H., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs232 · Cited by 111
Zwitterionic polymer-protein conjugates reduce polymer-specific antibody response
Liu, S., & Jiang, S. (2016) · Nano Today · doi:10.1016/j.nantod.2016.05.006 · Cited by 112
Besin, G., Milton, J., Sabnis, S., Howell, R., Mihai, C., Burke, K., Benenato, K. E., Stanton, M., Smith, P., Senn, J., et al. (2019) · ImmunoHorizons · doi:10.4049/immunohorizons.1900029 · Cited by 109
Li, A., Luehmann, H. P., Sun, G., Samarajeewa, S., Zou, J., Zhang, S., Zhang, F., Welch, M. J., Liu, Y., & Wooley, K. L. (2012) · ACS Nano · doi:10.1021/nn303030t · Cited by 106
AlQahtani, A. D., O’Connor, D., Dömling, A. S. S., & Goda, S. K. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108750 · Cited by 110
PASylation®: A versatile technology to extend drug delivery
Binder, U., & Skerra, A. (2017) · Current Opinion in Colloid & Interface Science · doi:10.1016/j.cocis.2017.06.004 · Cited by 116
De novo design of functional zwitterionic biomimetic material for immunomodulation
Li, B., Yuan, Z., Jain, P. R., Hung, H., He, Y., Lin, X., McMullen, P., & Jiang, S. (2020) · Science Advances · doi:10.1126/sciadv.aba0754 · Cited by 107
Antibodies against polyethylene glycol in human blood: A literature review
Lu, H., Wang, Z., Wei, X., Shi, J., & Li, C. (2020) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2020.106678 · Cited by 113
Developments in the scientific and clinical understanding of gout
So, A. K. L. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2509 · Cited by 100
Anti-PEG Antibodies Inhibit the Anticoagulant Activity of PEGylated Aptamers
Moreno, A., Pitoc, G. A., Ganson, N. J., Layzer, J. M., Hershfield, M. S., Tarantal, A. F., & Sullenger, B. A. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.02.001 · Cited by 103
Self-citationChen, W.-A., Chang, D.-Y., Chen, B., Lin, Y., Barenholz, Y., & Roffler, S. R. (2023) · ACS Nano · doi:10.1021/acsnano.2c12193 · Cited by 105
Immunological Risk of Injectable Drug Delivery Systems
Jiskoot, W., van Schie, R. M., Carstens, M. G., & Schellekens, H. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9855-9 · Cited by 107
Joh, D. Y., Zimmers, Z. A., Avlani, M., Heggestad, J. T., Aydın, H. B., Ganson, N. J., Kumar, S., Fontes, C. M., Achar, R. K., Hershfield, M. S., et al. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201801177 · Cited by 96
Self-citationShimizu, T., Ichihara, M., Yoshioka, Y., Ishida, T., Nakagawa, S., & Kiwada, H. (2012) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b12-00276 · Cited by 96
Liu, X., Li, H., Chen, Y., Jin, Q., Ren, K., & Ji, J. (2014) · Advanced Healthcare Materials · doi:10.1002/adhm.201300617 · Cited by 95
Pegylation and Its Impact on the Design of New Protein-Based Medicines
Ginn, C., Khalili, H., Lever, R., & Brocchini, S. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.125 · Cited by 102
Carreño, J. M., Singh, G., Tcheou, J., Srivastava, K., Gleason, C., Muramatsu, H., Desai, P., Aberg, J. A., Miller, R. L., PARIS study group, et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.08.024 · Cited by 95
Zwitterionic Nanocages Overcome the Efficacy Loss of Biologic Drugs
Li, B., Yuan, Z., Zhang, P., Sinclair, A., Jain, P. R., Wu, K., Tsao, C., Xie, J., Hung, H., Lin, X., et al. (2018) · Advanced Materials · doi:10.1002/adma.201705728 · Cited by 92
Determinants of the Clinical Outcomes of Gout During the First Year of Urate-Lowering Therapy
Becker, M. A., MacDonald, P. A., Hunt, B., Lademacher, C., & Joseph‐Ridge, N. (2008) · Nucleosides Nucleotides & Nucleic Acids · doi:10.1080/15257770802136032 · Cited by 86
Shimizu, T., Ishida, T., & Kiwada, H. (2012) · Immunobiology · doi:10.1016/j.imbio.2012.08.274 · Cited by 94
Site-selective protein modification with polymers for advanced biomedical applications
Liu, X., Sun, J., & Gao, W. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.04.050 · Cited by 86
Armstrong, J. K. (2009) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8679-5_9 · Cited by 81
d’Avanzo, N., Celia, C., Barone, A., Carafa, M., Marzio, L. D., Santos, H. A., & Fresta, M. (2020) · Advanced Therapeutics · doi:10.1002/adtp.201900170 · Cited by 88
Refractory gout: what is it and what to do about it?
Fels, E., & Sundy, J. S. (2008) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e3282f4eff5 · Cited by 79
Self-citationGorovits, B., Wakshull, E., Pillutla, R. C., Xu, Y., Manning, M. S., & Goyal, J. (2014) · Journal of Immunological Methods · doi:10.1016/j.jim.2014.05.010 · Cited by 81
Polymers for Protein Conjugation
Pasut, G. (2014) · Polymers · doi:10.3390/polym6010160 · Cited by 78
Clinical Relevance of Pre-Existing and Treatment-Induced Anti-Poly(Ethylene Glycol) Antibodies
Haddad, H. F., Burke, J. A., Scott, E. A., & Ameer, G. A. (2021) · Regenerative Engineering and Translational Medicine · doi:10.1007/s40883-021-00198-y · Cited by 83
Gout therapeutics and drug delivery
Peng, X., Li, X., Xie, B., Lai, Y., Sosnik, A., Boucetta, H., Chen, Z., & He, W. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.09.011 · Cited by 77
Anti-polyethyleneglycol Antibody Response to PEGylated Substances
Ishida, T., & Kiwada, H. (2013) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b13-00107 · Cited by 78
Nanotechnology in cell replacement therapies for type 1 diabetes
Ernst, A. U., Bowers, D. T., Wang, L., Shariati, K., Plesser, M. D., Brown, N. K., Mehrabyan, T., & Ma, M. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.01.013 · Cited by 85
Novel Tamoxifen Nanoformulations for Improving Breast Cancer Treatment: Old Wine in New Bottles
Day, C. M., Hickey, S. M., Song, Y., Plush, S. E., & Garg, S. (2020) · Molecules · doi:10.3390/molecules25051182 · Cited by 80
Özer, İ., Kelly, G., Gu, R., Li, X., Zakharov, N., Sirohi, P., Nair, S. K., Collier, J. H., Hershfield, M. S., Hucknall, A., et al. (2022) · Advanced Science · doi:10.1002/advs.202103672 · Cited by 77
Self-citationZhao, Y., Wang, C., Wang, L., Yang, Q., Tang, W., She, Z., & Deng, Y. (2012) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2012.04.023 · Cited by 74
Metadata
- Authors
- Ganson, N. J., Kelly, S. J., Scarlett, E., Sundy, J. S., & Hershfield, M. S.
- Affiliations
- Duke University (US)
- Duke Medical Center (US)
- Corresponding author
- Hershfield, Michael S
- Venue
- Arthritis Research & Therapy
- Published
- 2005-12-02
- Volume
- 8
- Issue
- 1
- Pages
- R12-R12
- ISSN
- 1478-6354 (ISSN-L)
- PMC
- PMC1526556
- OpenAlex
- W1918944513
- Cited by
- 350
- References
- 40
- Citations by year
- 2026: 10 · 2025: 14 · 2024: 14 · 2023: 13 · 2022: 13 · 2021: 16 · 2020: 27 · 2019: 24 · 2018: 18 · 2017: 11 · 2016: 20 · 2015: 11 · 2014: 22 · 2013: 17 · 2012: 28
- FWCI
- 10.61
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/2.0/ (tdm)
- creativecommons.org/licenses/by/2.0/ (vor)
- Locations
- Arthritis Research & Therapy (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Savient Pharmaceuticals
- National Institutes of Health (MO1-RR-30, RR-30)
- National Center for Research Resources (M01 RR 30, MO 1 RR-30)
- Topics
- Health Sciences › Medicine › Nephrology › Gout, Hyperuricemia, Uric Acid
- Health Sciences › Medicine › Pharmacology (medical) › Drug-Induced Adverse Reactions
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Keywords
- refractory gout, hyperuricemia, tophaceous gout, anti-PEG antibodies, subcutaneous injection, gout flares, injection site reactions
- MeSH terms
- Adult, Aged, Carbon Radioisotopes, Female, Gout, Humans, Immunoglobulin G, Male, Middle Aged, Polyethylene Glycols, Recombinant Proteins, Urate Oxidase, Urea, Uric Acid, Hyperuricemia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.